Skip to content

Clinical Performance of Two Reusable Silicone Hydrogel Contact Lenses

Clinical Performance of Two Reusable Silicone Hydrogel Contact Lenses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05431478
Enrollment
68
Registered
2022-06-24
Start date
2022-07-15
Completion date
2022-09-09
Last updated
2023-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Errors

Keywords

Myopia

Brief summary

The purpose of this study is to assess the clinical performance of two reusable silicone hydrogel contact lenses when worn on a daily wear basis.

Detailed description

In this crossover study, subjects will wear each study lens type for approximately 14 days and attend 7 scheduled visits. The expected duration of subject participation in the study is approximately 28 days (approximately 14 days per each study lens type).

Interventions

Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection

Reusable silicone hydrogel contact lenses worn during the day and removed at night for daily cleaning and disinfection

Hydrogen peroxide based contact lens cleaning and disinfecting solution

Sponsors

Alcon Research
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Key Inclusion Criteria: * Successful wear of spherical soft contact lenses in both eyes for a minimum of 5 days per week and 8 hours per day during the past 3 months. * Best Corrected Visual Acuity of 20/25 Snellen (0.10 logMAR) or better in each eye. * Willing to stop wearing habitual contact lenses for the duration of study participation. * Other protocol-specified inclusion criteria may apply. Key

Exclusion criteria

* Any eye infection, inflammation, abnormality or disease (including systemic) that contraindicates contact lens wear, as determined by the investigator. * Any use of systemic or ocular medications for which contact lens wear could be contraindicated, as determined by the investigator. * Habitual wear of AOHP contact lenses. * Habitual wear of any daily disposable contact lenses. * Other protocol-specified

Design outcomes

Primary

MeasureTime frameDescription
Visual Acuity With Study Lenses at Week 1 Follow-UpWeek 1, each wear period. A wear period was approximately 14 days.Visual acuity (VA) was assessed with study lenses in place using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity. Each eye was assessed individually. No hypothesis testing was pre-specified for this endpoint.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from 5 investigative sites located in the United States.

Pre-assignment details

This reporting group includes all enrolled participants/eyes (68/136).

Participants by arm

ArmCount
LID022821, Then AOHP
Serafilcon A contact lenses worn during Period 1, with senofilcon A contact lenses worn during Period 2, as randomized. Each study lens type was worn bilaterally (in both eyes) at least 10 hours per day for approximately 14 days. CLEAR CARE was used for daily cleaning and disinfection. The serafilcon A contact lenses were replaced with a fresh pair at the Week 1 follow-up visit.
34
AOHP, Then LID022821
Senofilcon A contact lenses worn during Period 1, with serafilcon A contact lenses worn during Period 2, as randomized. Each study lens type was worn bilaterally (in both eyes) at least 10 hours per day for approximately 14 days. CLEAR CARE was used for daily cleaning and disinfection. The serafilcon A contact lenses were replaced with a fresh pair at the Week 1 follow-up visit.
34
Total68

Baseline characteristics

CharacteristicLID022821, Then AOHPTotalAOHP, Then LID022821
Age, Continuous33.6 years
STANDARD_DEVIATION 7.1
32.3 years
STANDARD_DEVIATION 6.9
30.9 years
STANDARD_DEVIATION 6.5
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants3 Participants1 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
32 Participants65 Participants33 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Black or African American
0 Participants0 Participants0 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
34 Participants68 Participants34 Participants
Region of Enrollment
United States
34 participants68 participants34 participants
Sex: Female, Male
Female
25 Participants52 Participants27 Participants
Sex: Female, Male
Male
9 Participants16 Participants7 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
deaths
Total, all-cause mortality
0 / 680 / 1360 / 680 / 1360 / 68
other
Total, other adverse events
0 / 680 / 1360 / 680 / 1360 / 68
serious
Total, serious adverse events
0 / 680 / 1360 / 680 / 1360 / 68

Outcome results

Primary

Visual Acuity With Study Lenses at Week 1 Follow-Up

Visual acuity (VA) was assessed with study lenses in place using logarithmic of the Minimum Angle of Resolution (logMAR) charts. A logMAR acuity of 0.0 corresponds to 20/20 Snellen acuity (normal visual acuity), with a negative value denoting better than 20/20 visual acuity. Each eye was assessed individually. No hypothesis testing was pre-specified for this endpoint.

Time frame: Week 1, each wear period. A wear period was approximately 14 days.

Population: Safety Analysis Set.

ArmMeasureValue (MEAN)Dispersion
LID022821Visual Acuity With Study Lenses at Week 1 Follow-Up-0.12 logMARStandard Deviation 0.07
AOHPVisual Acuity With Study Lenses at Week 1 Follow-Up-0.11 logMARStandard Deviation 0.08

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026